The Role of Vitamin D3 in Pediatric Bronchiectasis Severity

• Status: Completed
• Trial end date: 2019-03-20
• Target enrollment: 0
• Participant gender: All

Summary

Vitamin D3 therapy was effective in decreasing the frequency of pulmonary exacerbations and preserving lung functions , thereby improving the disease severity even more in non CF than CF bronchiectasis patients

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Heba Omara
• Treatments: Cholecalciferol; Vitamin D

Criteria

Inclusion Criteria:

• ages less than 18 years .

• Patients with documented diagnosis of CF (by the presence of a twice positive sweat chloride test and or paired CFTR DNA genetic mutations).

• Patients with non CF bronchiectasis diagnosed clinically and radiologically ( sweat chloride test negative) with a high resolution CT-confirmed diagnosis and clinical history consistent with bronchiectasis .

• Vitamin D deficient or insufficient CF and non CF bronchiectasis patients

Exclusion Criteria: if they had

• sufficient Vitamin D level .

• chronic lung diseases other than CF and non CF bronchiectasis , liver or renal diseases.

• reported taking vitamin-D supplements or steroid therapy in the last 6 weeks.